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Abstract 
Introduction: We aimed to investigate the role of sTWEAK in the pathogenesis of Hashimoto’s thyroiditis, which is a chronic inflamma-
tory autoimmune disease.
Material and methods: A total of 80 patients were included in the study, 60 of whom were newly diagnosed with Hashimoto’s thyroiditis 
(20 patients in each of the euthyroid, subclinical hypothyroid, and overt hypothyroid subgroups), and 20 of whom were healthy volunteers. 
Thyroid function tests and autoantibodies were measured using the electro-chemiluminescence immunoassay method, and sTWEAK, 
IL-17A, IL-12, and TGF-b1 were measured using enzyme-linked immunosorbent assay method.
Results: The Hashimoto’s Thyroiditis group had lower levels of sTWEAK and TGF-b1, but had higher levels of IL-12 and IL-17A as com-
pared to the control group. Of these, only the difference between IL-17A levels reached statistical significance (2.1 pg/mL vs. 1.8 pg/mL, 
respectively; p < 0.001). While the levels of sTWEAK were similar in the control, euthyroid, and subclinical groups, the overt hypothyroid-
ism group had lower level of sTWEAK than that of subclinical hypothyroidism (687.6 ± 153.3 pg/mL vs. 888.2 ± 374.4 pg/mL, respectively; 
p = 0.03). A negative correlation was determined between sTWEAK level and anti-TPO (r = –0.533, p = 0.028) and IL-17A (r = –0.600, 
p = 0.005) levels in the overt hypothyroidism group.
Conclusions: The reduced levels of sTWEAK with progression of Hashimoto’s Thyroiditis and the significant correlation between the 
sTWEAK levels and anti-TPO found in this study suggest that sTWEAK plays an active role in chronic inflammation in the pathogenesis 
of Hashimoto’s Thyroiditis and in the progression of autoimmunity. (Endokrynol Pol 2016; 67 (6): 562–566)
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Streszczenie
Wstęp: Badanie przeprowadzono w celu ustalenia roli sTWEAK w patogenezie zapalenia tarczycy Hashimoto, przewlekłej zapalnej 
choroby autoimmunologicznej.
Materiał i metody: Do badania włączono łącznie 80 chorych, w tym 60 osób z nowo rozpoznaną chorobą Hashimoto (po 20 chorych w 
podgrupach z eutyreozą, subkliniczną niedoczynnością tarczycy i jawną niedoczynnością tarczycy) i 20 zdrowych ochotników. Badania 
czynności tarczycy oraz oznaczenia stężenia autoprzeciwciał przeprowadzono przy użyciu metod elektrochemiluminescencji, a stężenia 
sTWEAK, IL-17A, IL-12 i TGF-b1 oznaczono za pomocą testów enzymatycznych.
Wyniki: W grupie osób z chorobą Hashimoto stężenia sTWEAK i TGF-b1 były niższe, a stężenia IL-12 i IL-17A wyższe niż w grupie kon-
trolnej. Jednak tylko różnice między stężeniami IL-17A osiągnęły poziom istotności statystycznej (odpowiednio 2,1 pg/ml vs. 1,8 pg/ml; 
p < 0,001). Podczas gdy stężenia sTWEAK były podobne w grupach kontrolnej, z eutyreozą i z subkliniczną niedoczynnością tarczycy, 
stężenia sTWEAK w grupie z jawną niedoczynnością tarczycy były niższe niż u osób z subkliniczną niedoczynnością tarczycy (odpowiednio 
687,6 ± 153,3 pg/ml vs. 888,2 ± 374,4 pg/ml; p = 0,03). Stwierdzono ujemną korelację między stężeniem sTWEAK a stężeniami przeciwciał 
przeciw TPO (r = –0,533; p = 0,028) oraz IL-17A (r = –0,600; p = 0.005) w grupie z jawną niedoczynnością tarczycy.
Wnioski: Obniżanie się stężenia sTWEAK z progresją choroby Hashimoto oraz istotna korelacja między stężeniem sTWEAK a stężeniem 
przeciwciał przeciw TPO stwierdzone w tym badaniu wskazują, że sTWEAK odgrywa aktywną rolę w przewlekłym zapaleniu w pato-
genezie choroby Hashimoto, a także w progresji autoagresji. (Endokrynol Pol 2016; 67 (6): 562–566)
Słowa kluczowe: zapalenie tarczycy Hashimoto; IL-12; IL-17A; sTWEAK; TGF-b1
Introduction
Hashimoto’s thyroiditis (HT) is the most common or-
gan-specific autoimmune disease and the most common 
cause of hypothyroidism. Many genetic and environ-
mental factors are responsible for the aetiology in HT, 
and T cell-mediated autoimmunity plays an important 
role in its pathogenesis. CD4+ Th1 cells, through cy-
tokines, induce CD8+ cytotoxic Th2 cells in the thyroid 
gland as a result of infiltration of T and B cells with 
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reactivity of thyroid autoantigens and loss of immune 
tolerance, and initiate the apoptotic process, resulting 
in destruction of thyroid cells [1]. Th1 is dominant over 
autoimmunity in HT whereas Th 2 is often responsible 
for autoimmunity in Graves’ disease. Th1 synthesises 
the proinflammatory cytokines (IL-2, IFN-g, TNF, IL-1b, 
IL-12) and has a cytotoxic effect [2]. One subgroup of 
CD4 + T lymphocytes is Th3 cell, known as regulator 
T cell or Treg, which is responsible for regulation of 
adaptive immune system and synthesis of TGF-b1. 
TGF-b1 is a cytokine that inhibits the reproduction of 
T and B cells and the cytotoxicity of T cells [3]. TGF-b1 
has a protective function from autoimmune thyroid 
disease. Another subgroup of T cells is the recently 
emerging IL-17, which is synthesised by Th17 and has 
a role in autoimmune diseases [4]. IL-17 and IL-12 have 
been shown to increase and TGF-b1 has been shown to 
reduce in HT and other several autoimmune diseases. 
Tumor necrosis factor like weak inducer of apoptosis 
(TWEAK), is a member of the tumor necrosis factor 
superfamily (TNFSF) and binds to fibroblast growth 
factor-inducible molecule 14 (Fn14) receptor and plays 
a role in cellular proliferation, migration, apoptosis, 
differentiation, angiogenesis, and inflammation via 
nuclear factor kB (NF-kB) pathway [5]. There are two 
active forms of TWEAK: membrane-bounded mTWEAK 
and its soluble form sTWEAK. 
Proinflammatory cytokines, which are synthesised 
by Th1 lymphocytes, often play a role in the pathogen-
esis of autoimmune diseases. These proinflammatory 
cytokines increase the immunogenicity of antigenic 
structures in thyroid gland and similar tissues, which 
results in increased levels of autoantibody in IL-4, IL-5, 
and B lymphocytes. Because TWEAK is a subgroup 
of TNFSF that is synthesised by Th1 lymphocytes, we 
consider that TWEAK may play a role in increased 
autoimmune response. Indeed, a number of previous 
studies have shown that TWEAK is associated with 
the aetiopathogenesis of several autoimmune diseases 
(systemic lupus erythematosus [SLE], multiple sclerosis, 
type 1 diabetes mellitus, etc.) [6, 7].
However, it is not known whether TWEAK plays 
a role in the aetiopathogenesis of HT, which is an au-
toimmune disease. Therefore, we aimed to investigate 
the role of sTWEAK in the pathogenesis of HT and its 
relationship with IL-12, IL-17A, and TGF-b1.
Material and methods
This study was conducted at the Internal Medicine Clin-
ic of Ankara Numune Training and Research Hospital 
between April and June, 2015. The study was conducted 
in accordance with the Declaration of Helsinki and was 
approved by the Local Ethics Research Committee. All 
subjects provided written, informed consent prior to 
participation in the study.
A total of 80 patients over the age of 18 years were 
included in the study: 60 patients newly diagnosed with 
HT, who did not receive any treatment, and 20 patients 
with no known disease as the healthy control group. 
The exclusion criteria were other known systemic 
or metabolic diseases such as malignancy, infection, 
diabetes mellitus, atherosclerosis, and history of regular 
use of drugs. 
Diagnosis of HT was established by increased se-
rum levels of anti-thyroglobulin (anti-TG) and/or anti-
thyroid peroxidase (anti-TPO) and/or the presence of 
heterogeneous echogenicity in the thyroid parenchyma 
demonstrated on the thyroid ultrasonography. Serum 
thyroid stimulating hormones (TSH), free thyroxine 
(fT4), anti-TG, and anti-TPO were measured for those 
to be included in the control group, and HT was 
eliminated by thyroid ultrasonography, which was 
performed separately. 
Biochemical parameters
After completing medical history taking and physical 
examination of the patient and control groups, serum 
samples were collected following a 12-hour fast, centri-
fuged, and kept at –80°C. Then sTWEAK, IL-17A, IL-12 
and TGF-b1 were collectively measured.
Serum IL-17A concentrations were measured using 
a commercial ELISA kit (eBioscience, An Affymetrix 
Company, Austria). The limit of detection was 0.5 pg/ml. 
Intra and inter-assay precisions were 7.1% and 9.1%, 
respectively. 
Serum IL-12p70 concentrations were measured us-
ing a commercial ELISA kit (eBioscience, An Affymetrix 
Company, Austria). The limit of detection was 2.1 pg/ml. 
Intra and inter-assay precisions were 3% and 4.8%, 
respectively. 
Serum TGF-b1 concentrations were measured 
using a commercial ELISA kit (eBioscience, An Affy-
metrix Company, Austria). The limit of detection was 
0.008 ng/mL. Intra and inter-assay precisions were 3.2% 
and 4.9%, respectively. 
Serum sTWEAK concentrations were measured 
using a commercial ELISA kit (eBioscience, An Affy-
metrix Company, Austria). The limit of detection was 
9.7 pg/ml. Intra and inter-assay precisions were 7.9% 
and 9.2%, respectively.
Statistical analysis
The findings of this study were analysed with the Sta-
tistical Package for Social Sciences for Windows (SPSS 
v18) software. The conformity of continuous variables 
to normal distribution was tested with Kolmogorov-
Smirnov test. The descriptive statistics of continuous 
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variables were expressed as mean ± SD or median 
(min-max). During the comparisons, Student t test for 
parametric and Mann-Whitney test for nonparametric 
variables was performed. In the subgroup analysis, 
the presence of a statistically significant differences be-
tween the groups in terms of continuous variables was 
examined with ANOVA for parametric and Kruskall 
Wallis test for non-parametric variables. Post hoc test-
ing was performed where the overall significance of 
the ANOVA or Kruskall Wallis test was significant 
(p < 0.05). Pearson correlation analysis was used for 
correlation of the variables.
Results
Table I shows the demographic characteristics of pa-
tient and control groups and the measurement results. 
Both of the groups had similar characteristics such as 
age, gender, and body mass index. The HT group had 
lower levels of sTWEAK and TGF-b1, but had higher 
levels of IL-12 and IL-17A as compared to the control 
group. Of these, only the difference between IL-17A 
levels reached statistical significance (2.1 pg/mL vs. 
1.8 pg/mL, respectively; p < 0.001). 
Table II shows in detail the levels of demographic and 
laboratory findings according to HT subgroups and con-
trol group. The level of sTWEAK was found to be similar 
in the control, euthyroid, and subclinical hypothyroid-
ism groups. The subclinical hypothyroidism group had 
a higher level of sTWEAK than that of overt hypothy-
roidism (888.2 ± 374.4 pg/mL vs. 687.6 ± 153.3 pg/mL, 
respectively; p = 0.03). No significant differences were 
detected in TGF-b1 levels between groups. While the 
levels of IL-12 were similar in the control, euthyroid, 
and subclinical hypothyroidism groups, its level in the 
overt hypothyroidism group was higher than that of the 
euthyroid and control groups (3.6 pg/mL vs. 2.7 pg/mL 
vs. 2.7 pg/mL, respectively; p < 0.01). The level of IL-17A 
was higher in all HT subgroups than that of the control 
group; however, its level was higher in the subclinical 
and overt hypothyroidism groups than that of the eu-
thyroid group among HT subgroups (control: 1.8 pg/ 
/mL, euthyroid: 2 pg/mL, subclinical hypothyroidism: 
2.3 pg/mL, overt hypothyroidism: 2.3 pg/mL; p < 0.01).
When we examined the relation between demo-
graphic, clinical, and laboratory parameters in the HT 
group we determined a positive correlation between 
IL-12 level and anti-TPO (r = 0.496, p < 0.001) level. 
A positive correlation was determined between 
sTWEAK level and TGF-b1 level (r = 0.278, p = 0.032). 
In the HT subgroup analysis, we determined a nega-
tive correlation between sTWEAK level and anti-TPO 
(r = –0.533, p = 0.028), IL-17A (r = –0.600, p = 0.005) 
levels in overt hypothyroidism group. 
Discussion 
In the present study, the overt hypothyroidism group 
had a low sTWEAK level as compared to the subclini-
cal hypothyroidism group. The level of sTWEAK was 
similar in the control, euthyroid, and subclinical hypo-
thyroidism groups. There was a negative correlation 
between anti-TPO and IL-17A in the overt hypothyroid-
ism group. As far as we know, this study is the first to 
determine the level of sTWEAK in HT and to investigate 
its relationship with thyroid autoantibodies.
Soluble TWEAK is a multifunctional cytokine that 
induces apoptosis in one cell while activating cell 
reproduction in another cell. It induces many cel-
lular response and regulates inflammatory pathways 
depending on the cell type and micro environment 
[8]. The biological activity of sTWEAK may vary by 
onset period of inflammation. After acute tissue injury, 
sTWEAK induces progenitor cells and enables tissue 
regeneration, and alters tissue repair by inhibiting 
differentiation of the same progenitor cells following 
Table I. Demographical and biochemical features of controls 
and Hashimoto’s Thyroiditis patients
Tabela I. Charakterystyka demograficzna i parametry 
biochemiczne osób z grupy kontrolnej i pacjentów z chorobą 
Hashimoto
Variables Hashimoto’s 
Thyroiditis
Control p
n (60) n (20)
Age (years) 31.5 ± 8.8 32.7 ± 7.4 0.62
Gender, n (f/m) 53/7 17/3 0.23
BMI [kg/m2] 24.1 ± 2.8 23.9 ± 2.5 0.82
SBP [mm Hg] 117 (90–185) 110 (90–125) 0.09
DBP [mm Hg] 69.5 (53–90) 70 (60–80) 0.61
TSH [µIU/mL] 7 (0.9–500) 1.6 (0.9–3.5)  < 0.01*
fT3 [pg/mL] 2.6 ± 0.8 2.8 ± 0.5 0.22
fT4 [ng/dL] 0.9 ± 0.3 1.2 ± 0.4 0.02*
Anti-TG [IU/mL] 234.9 (10–7411) 7.6 (2.4–26)  < 0.01*
Anti-TPO [IU/mL] 168.5 (4.2–4578) 3.9 (1–39)  < 0.01*
sTWEAK [pg/mL] 780.4 ± 266.3 865.1 ± 218.5 0.23
TGF-b1 [ng/mL] 16.9 (0.4–205.8) 29.4 (0.3–153.1) 0.24
IL-12 [pg/mL] 3 (2.1–29.1) 2.7 (1.9–4.2) 0.07*
IL-17A [pg/mL] 2.1 (1.1–10.7) 1.8 (1.2–2.3)  < 0.01*
*p < 0.05 shows statistical significance.
BMI — body mass index, SBP — systolic blood pressure, DBP — diastolic blood 
pressure, TSH — thyroid stimulating hormone, fT3 — triiodothyronin, fT4 — 
levothyroxine, Anti-TG — anti-thyroglobulin, anti-TPO — anti-thyroid peroxidase, 
sTWEAK — soluble tumour necrosis factor like weak inducer of apoptosis, 
TGF-b1 — transforming growth factor beta,1 IL-17A — interleukin 17A,  
IL-12 — interleukin 12
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chronic injury [9]. A large part of data increasingly 
highlight the contribution of sTWEAK/Fn14 pathway to 
inflammation in autoimmune diseases [10]. Literature 
has no studies investigating the relationship between 
the serum sTWEAK and HT, an autoimmune disease. 
In evaluation of studies examining the association of 
other autoimmune diseases with sTWEAK, a study by 
Albert Einstein College of Medicine on SLE and healthy 
control group reported that SLE patients had relatively 
lower levels of sTWEAK than those of a healthy con-
trol group [11]. Similarly, a study by Noa Schwartz et 
al. identified lower levels of sTWEAK in SLE patients 
as compared to a healthy control group [11]. In addi-
tion, many studies with animal and human models 
indicate that sTWEAK might be associated with the 
aetiopathogenesis of multiple sclerosis [12]. Further-
more, since sTWEAK has been shown to be associated 
with the pathophysiology of rheumatoid arthritis and 
SLE, recent studies have focused on the effect of anti-
TWEAK therapies on the prognosis of the disease in 
such diseases 
In this study, the level of sTWEAK was found to 
be similar in the control, euthyroid, and subclinical 
hypothyroidism groups. The overt hypothyroidism 
group had lower level of sTWEAK as compared to the 
subclinical hypothyroidism group. Normally, because 
TWEAK is a proinflammatory cytokine, we expect the 
level of TWEAK to increase in inflammatory events. 
However, this study detected the level of sTWEAK to 
be low. Low serum level of sTWEAK in HT might have 
resulted from the increased Fn-14 level, which bound to 
sTWEAK and decreased the serum level of sTWEAK in 
chronic inflammation [13], or the increased level of CD 
163, a scavenger receptor, which causes sTWEAK to be 
destructed by inflammatory macrophages in the case of 
inflammation [14]. A result of this study that supports 
the possible explanations provided above is that the 
level of IL-17A, a proinflammatory cytokine, increased 
from the control group to the overt hypothyroidism 
group. A negative correlation found between sTWEAK 
and IL-17A strongly supports our hypothesis. 
The lower level of sTWEAK found in the overt 
hypothyroidism group than that of the subclinical hy-
pothyroidism group had several possible causes. The 
first one might be the significant insufficiency of thyroid 
hormone, the second one might be the excessive chronic 
inflammation, and the most important one might be 
the increased autoimmune response. Lack of correla-
tion between the thyroid function test and sTWEAK 
in the correlation analysis refutes our first hypothesis. 
As the pathogenesis of HT has a chronic inflamma-
tory process, the expected finding is that the level of 
sTWEAK, a proinflammatory cytokine, varied with 
the progression of the disease. Our second hypothesis 
Table II. Comparison of subgroups of the HT patients and controls
Tabela II. Porównanie podgrup pacjentów z chorobą Hashimoto i osób z grupy kontrolnej
Variables Control Euthyroid Subclinical hypothyroidism Overt hypothyroidism p
n (20) n (20) n (20) n (20)
Age (years) 35.3 ± 7.5 32.5 ± 8.2 30.9 ± 9.9 31.9 ± 8.2 0.91
Gender, n (f/m) 2/18 1/19 2/18 3/17 0.24
BMI [kg/m2] 24.6 ± 2.3 23.6 ± 2 25.1 ± 3 24 ± 3.3 0.62
SBP [mm Hg] 110 (90–125) 118.5 (100–128) 110 (90–132) 116 (90–135) 0.08
DBP [mm Hg] 70 (60–80) 62.5 (56–87) 70 (53–90) 72.5 (60–85) 0.02a, d, e
TSH [µIU/mL] 1.6 (0.9–3.5) 2.1 (0.9–4.2) 7.1 (4.6–14.5) 33.3 (9.6–207.6) 0.01a, b, c, d, e, f
fT3 [pg/mL] 2.8 ± 0.5 2.8 ± 0.4 3 ± 0.4 2.2 ± 0.8  < 0.01b, d, f
fT4 [ng/dL] 1.2 ± 0.5 1.2 ± 0.1 1.1 ± 0.1 0.6 ± 0.1  < 0.01c
Anti–TG [IU/mL] 7.6 (2.4–26) 207.1 (16.7–1538) 219 (10–3910) 341 (59.4–7411)  < 0.01a, b, c
Anti–TPO [IU/mL] 3.9 (1–39) 43.1 (5–443) 119 (4–9578) 515.5 (6–7977)  < 0.01a, b, c, d, e, f
sTWEAK [pg/mL] 838.5 ± 236.5 771.4 ± 215.4 888.2 ± 374.4 687.6 ± 153.3 0.04f
TGF–b1 [ng/mL] 29.4 (0.3–153.1) 7.3 (0.5–104.6) 27 (0.6–205.8) 15.7 (0.5–97.5) 0.24
IL–12 [pg/mL] 2.7 (1.9–4.2) 2.7 (2.2–5.8) 3.1 (2.1–29.1) 3.6 (2.4–7.6)  < 0.01c, e
IL–17A [pg/mL] 1.8 (1.2–2.3) 2 (1.1–2.7) 2.3 (1.6–10.7) 2.4 (1.5–7.8)  < 0.01a, b, c, d, e
aControl vs. Euthyroid, bControl vs. subclinical Hypothyroidism, cControl vs. Overt hypothyroidism, dEuthyroid vs. Subclinical hypothyroidism, eEuthyroid vs. Overt 
hypothyroidism, fSubclinical hypothyroidism vs. Overt hypothyroidism.
BMI — body mass index, SBP — systolic blood pressure, DBP — diastolic blood pressure, TSH — thyroid stimulating hormone, fT3 — triiodothyronin,  
fT4 — levothyroxine, Anti-TG — anti-thyroglobulin, anti-TPO — anti-thyroid peroxidase, sTWEAK — soluble tumor necrosis factor like weak inducer of apoptosis, 
TGF-b1 — transforming growth factor beta,1 IL-17A — interleukin 17A, IL-12 — interleukin 12
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is therefore acceptable. We consider that the primary 
cause of variation of the level of sTWEAK as compared 
to subclinical hypothyroidism could be the increased 
autoimmune response in the overt hypothyroidism 
group. Our hypothesis is strongly supported by the 
higher level of anti-TPO in the overt hypothyroidism 
group compared to all other groups, and by the strong 
correlation found between the level of sTWEAK and 
anti-TPO in the overt hypothyroidism group. 
Another cytokine is IL-17A, which is synthesised 
by Th17 and has a role in proinflammation with many 
cytokines. Recently, the association of IL-17A with auto-
immune diseases has often been underlined. In studies 
conducted with HT, Graves disease, and healthy control 
groups, HT had significantly higher levels of IL-17A 
than those of Graves and healthy control groups [15-18]. 
Dapeng Li et al. reported negative correlation between 
the IL-17A level and the extent of hypothyroidism in 
HT. In the same study, increased levels of IL-17A both 
in thyroid gland and in serum suggested that IL-17A 
played an active role in the pathogenesis of HT [15]. 
Data from our study support the role of IL-17A in HT. 
A previous study reported that euthyroid and overt 
hypothyroidism with HT had higher levels of IL-12 
compared to the control group, and the hypothyroid-
ism group had higher IL-12 levels compared to the 
euthyroid group within the HT group [19]. Another 
study reported that the euthyroid HT group had sig-
nificantly higher levels of IL-12 than those of a healthy 
control group [20]. In our study, the levels of IL-12 were 
found to be similar to those in the studies above in the 
HT group and subgroup analyses. Th1 is said to play 
a dominant role in inflammation of HT [2]. Increased 
level of IL-12, synthesised by Th1, in the HT group of 
our study is consistent with that hypothesis. 
In studies conducted with TGF-b1, TGF-b1 level was 
significantly lower in patients with HT compared to 
the healthy control group, and its level was reported to 
decrease further towards late phase of disease [21–23]. 
In fact, it is not surprising to identify the TGF-b1 level to 
be low in HT, because the immunosuppressive effect of 
TGF-b1 is known well. Absence or low level of TGF-b1 
contributes to activation and differentiation of T cells 
and development of autoimmune diseases by initiating 
apoptosis [22]. We found TGF-b1 levels to be lower in 
the HT group than those of the healthy control group, 
but this was not statistically significant. This might be 
related to our patients in the HT group, who were only 
at the onset phase of the disease. 
The critical limitations of this study are the insuf-
ficient number of cases and controls. In addition, the 
second major limitation of our study was that fn14 and 
CD163 levels were not determined, which began to 
increase with TWEAK levels in the pro-inflammatory 
process and acted on the reduced level of circulating 
TWEAK.
As a result the reduced level of sTWEAK with 
HT progression and significant relationship between 
sTWEAK level and anti-TPO found in our study suggest 
that sTWEAK played an active role in chronic inflamma-
tion in the pathogenesis of HT and in the progression 
of autoimmunity. Further studies are needed to clearly 
understand the active role of sTWEAK in autoimmune 
process in HT, which is an autoimmune thyroiditis.
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